Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence

Darici, S; Alkhaldi, H; Horne, G; Jorgensen, HG; Marmiroli, S; Huang, X

Darici, S; Huang, X (corresponding author), Univ Glasgow, Paul OGorman Leukaemia Res Ctr, Haematooncol Syst Med Grp, Glasgow G12 0ZD, Lanark, Scotland.; Darici, S (corresponding author), Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, I-41124 Modena, Italy.

JOURNAL OF CLINICAL MEDICINE, 2020; 9 (9):

Abstract

Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy characterized by excessive proliferation and accumulation of immature ......

Full Text Link